Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Published
Correlación entre escalas de apoyo para el diagnóstico de demencia o alteraciones cognitivas con Síndrome de Down
Correlation between Support Scales for the Diagnosis of Dementia or Cognitive Impairment in People with Down Syndrome
Correlação entre escalas de apoio para o diagnóstico de demência ou comprometimento cognitivo em pessoas com síndrome de Down
DOI:
https://doi.org/10.15446/av.enferm.v43n2.121467Keywords:
Demencia, Disfunción Cognitiva, Enfermedad de Alzheimer, Envejecimiento Prematuro, Pruebas de Estado Mental y Demencia, Síndrome de Down (es)Dementia, Cognitive Dysfunction, Alzheimer’s disease, Premature Aging, Mental Status and Dementia Tests, Down Syndrome (en)
Demência, Disfunção Cognitiva, Doença de Alzheimer, Envelhecimento Precoce, Testes de Estado Mental e Demência, Sindrome de Down (pt)
Downloads
Introducción: debido a la sobreexpresión de genes localizados en el cromosoma 21, las personas con síndrome de Down (SD) presentan una predisposición genética al envejecimiento prematuro y al desarrollo de la enfermedad de Alzheimer. La CAMCOG -DS es un instrumento validado para la valoración cognitiva en personas con SD; sin embargo, su acceso desde el Sistema Nacional de Salud es limitado.
Objetivo: analizar la correlación entre las escalas de apoyo utilizadas para el diagnóstico de demencia o alteraciones cognitivas en personas con SD.
Metodología: estudio observacional, transversal y correlacional. La muestra, previamente evaluada mediante la escala CAMCOG-DS, fue valorada con las escalas SPMSQ y MEC. Posteriormente, se analizó la correlación entre los resultados obtenidos mediante el programa JASP.
Resultados: no se hallaron evidencias estadísticamente significativas que permitieran correlacionar los resultados de la escala MEC con los de la escala SPMSQ en la evaluación de personas con SD. Tampoco se obtuvo significación estadística al correlacionar los resultados de las escalas CAMCOG -DS y SPMSQ. No obstante, sí se observó significación estadística en la correlación entre los resultados de la CAMCOG-DS y la MEC.
Conclusiones: con las características y el diseño del presente estudio, no se obtuvieron evidencias estadísticamente significativas que permitan establecer una
relación entre los resultados de las escalas CAMCOG -DS, SPMSQ de Pfeiffer y MEC de Lobo en la muestra evaluada. Sin embargo, la correlación leve observada entre la CAMCOG -DS y la MEC abre posibles líneas futuras de investigación orientadas a proporcionar herramientas útiles para el profesional sanitario.
Introduction: Due to the overexpression of genes located on chromosome 21, people with Down syndrome (DS) have a genetic predisposition to premature aging and the development of Alzheimer’s disease. CAMCOG -DS is a validated instrument for cognitive assessment in people with DS; however, access to this tool within the National Health System is limited.
Objective: To analyze the correlation between support scales used for the diagnosis of dementia or cognitive impairment in people with DS.
Methodology: An observational, cross-sectional, correlational study was conducted. The sample, previously assessed using the CAMCOG-DS scale, was evaluated with the SPMSQ and the MEC. Subsequently, correlations between the results were analyzed using the JASP software.
Results: No statistically significant evidence was found to support a correlation between the results of the MEC scale and the SPMSQ in the assessment of people with DS. Likewise, no statistical significance was observed when correlating the results of the CAMCOG-DS and SPMSQ scales. However, a statistically significant correlation was observed between the CAMCOG-DS and the MEC results.
Conclusions: Given the characteristics and design of the present study, no statistically significant evidence was obtained to establish a relationship between the results of the CAMCOG-DS , Pfeiffer’s SPMSQ, and Lobo’s MEC in the evaluated sample. Nevertheless, the weak correlation observed between CAMCOG-DS and MEC opens potential avenues for future research aimed at providing useful tools for healthcare professionals.
Introdução: Em decorrência da superexpressão de genes localizados no cromossomo 21, as pessoas com síndrome de Down (SD) apresentam predisposição genética ao
envelhecimento precoce e ao desenvolvimento da doença de Alzheimer. A CAMCOG-DS é um instrumento validado para a avaliação cognitiva em pessoas com SD; entretanto,
o acesso a essa ferramenta no âmbito do Sistema Nacional de Saúde é limitado.
Objetivo: Analisar a correlação entre as escalas de apoio utilizadas para o diagnóstico de demência ou comprometimento cognitivo em pessoas com SD.
Metodologia: Foi realizado um estudo observacional, transversal e correlacional. A amostra, previamente avaliada por meio da escala CAMCOG -DS, foi submetida às escalas SPMSQ e MEC. Posteriormente, as correlações entre os resultados obtidos foram analisadas com o auxílio do software JASP.
Resultados: Não foram encontradas evidências estatisticamente significativas que sustentem uma correlação entre os resultados da escala MEC e da escala SPMSQ na avaliação de pessoas com SD. Da mesma forma, não foi observada significância estatística na correlação entre os resultados das escalas CAMCOG-DS e SPMSQ. Contudo, identificou-se uma correlação estatisticamente significativa entre os resultados da CAMCOG-DS e do MEC.
Conclusões: Considerando as características e o delineamento do presente estudo, não se obtiveram evidências estatisticamente significativas que permitam estabelecer uma relação entre os resultados da CAMCOG-DS, do SPMSQ de Pfeiffer e do MEC de Lobo na amostra avaliada. Ainda assim, a correlação fraca observada entre a CAMCOG-DS e o MEC abre perspectivas para futuras pesquisas voltadas à disponibilização de ferramentas úteis para os profissionais de saúde.
References
(1) Antonarakis SE; Skotko BG; Rafii MS; Strydom A; Pape SE; Bianchi DW et al. Down syndrome. Nat Rev Dis Primers. 2020;6:9. https://doi.org/10.1038/s41572-019-0143-7
(2) Wallace ER; Harp JP; Van Pelt KL; Koehl LM; Caban-Holt AM; Anderson-Mooney AJ et al. Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities. J Intellect Disabil Res. 2021;65(12):1085–1096. https://doi.org/10.1111/jir.12901
(3) Alldred MJ; Martini AC; Patterson D; Hendrix J; Granholm AC. Aging with Down syndrome—Where are we now and where are we going? J Clin Med. 2021;10(20):4687. https://doi.org/10.3390/jcm10204687
(4) Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L et al. Association of apolipoprotein E ɛ4 allele with clinical and multimodal biomarker changes of Alzheimer disease in adults with Down syndrome. JAMA Neurol. 2021;78(8):937–947. https://doi.org/10.1001/jamaneurol.2021.1893
(5) Nadeau PA; Jobin B; Boller B. Diagnostic sensitivity and specificity of cognitive tests for mild cognitive impairment and Alzheimer’s disease in patients with Down syndrome: A systematic review and meta-analysis. J Alzheimers Dis. 2023;95(1):13–51. https://doi.org/10.3233/JAD-220991
(6) Instituto Nacional de Estadística. Pirámide de Población en España. 2025. https://www.ine.es/covid/piramides.htm
(7) Liu RM. Aging, cellular senescence, and Alzheimer's disease. Int J Mol Sci. 2022;23(4):1989. https://doi.org/10.3390/ijms23041989
(8) Instituto Nacional de Estadística. Defunciones según la causa de muerte. Año 2022. España. 2023. https://www.ine.es/prensa/edcm_2022.pdf
(9) Jannati A; Toro-Serey C; Gomes-Osman J; Banks R; Cielsa M; Showalter J et al. Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia. Alz Res Therapy. 2024;16(2). https://doi.org/10.1186/s13195-023-01367-7
(10) Quintanilla M. La medida de la dependencia. Escalas de valoración. En: Acebes E, editor. Enfermería en cuidados sociosanitarios. Madrid: Difusión Avances de Enfermería (DAE ); 2005. p. 55–88.
(11) Gensous N; Bacalini MG; Franceschi C; Garagnani P. Down syndrome, accelerated aging and immunosenescence. Semin Immunopathol. 2020;42:635–645. https://doi.org/10.1007/s00281-020-00804-1
(12) Fonseca LM; Ball SL; Holland AJ. The Cambridge Examination for Mental Disorders of Older People with Down’s Syndrome and Others with Intellectual Disabilities (CA MDEX-DS). En: Prasher V, editor. Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Cham: Springer; 2018. https://doi.org/10.1007/978-3-319-61720-6_7
(13) Walsh DM; Doran E; Silverman W; Tournay A; Movsesyan N; Lott IT. Rapid assessment of cognitive function in Down syndrome across intellectual level and dementia status. J Intellect Disabil Res. 2015;59(11):1071–1079. https://doi.org/10.1111/jir.12200
(14) Ball S; Holland T; Huppert F; Treppner P; Dodd K. CA MDEX-DS. Prueba de Exploración Cambridge para la valoración de los trastornos mentales en adultos con Síndrome de Down o con Discapacidad Intelectual. Madrid: TEA Ediciones S.A.U.; 2013.
(15) Domínguez García J; Navas Macho P. Deterioro cognitivo y trastorno neurodegenerativo en personas con discapacidad intelectual. Siglo Cero. 2018;49(1):53–67. https://doi.org/10.14201/scero20184915367
(16) Fundación Asindown. Asindown Vida Adulta y Envejecimiento. 2024. https://asindown.org/asindown-vida-adulta-y-envejecimiento-activo/#
(17) American Psychiatric Association. Guía de consulta de los criterios diagnósticos del DSM-5. Madrid: Editorial Médica Panamericana; 2014.
(18) Goss-Sampson M; Meneses J. Análisis estadístico con JAS P: una guía para estudiantes. Universitat Oberta de Catalunya. 2019. http://hdl.handle.net/10609/102926
(19) Horvath S; Garagnani P; Bacalini MG; Pirazzini C; Salvioli S; Gentilini D et al. Accelerated epigenetic aging in Down syndrome. Aging Cell. 2015;14(3):491–495. https://doi.org/10.1111/acel.12325
(20) Bayen E; Possin KL; Chen Y; Cleret de Langavant L; Yaffe K. Prevalence of aging, dementia, and multimorbidity in older adults with Down syndrome. JAMA Neurol. 2018;75(11):1399–1406. https://doi.org/10.1001/jamaneurol.2018.2210
(21) Silverman W; Krinsky-McHale SJ; Lai F; Rosas HD; Hom C; Doran E et al. Evaluation of the National Task Group‐Early Detection Screen for Dementia: Sensitivity to “mild cognitive impairment” in adults with Down syndrome. J Appl Res Intellect Disabil. 2021;34(3):905–915. https://doi.org/10.1111/jar.12849
(22) Nuebling G; Wagemann O; Deb S; Wlasich E; Loosli SV; Sandkühler K; Stockbauer A; Prix C and Levin, J. Validation of a German version of the dementia screening questionnaire for individuals with intellectual disability (DS QIID ) in Down syndrome. J Appl Res Intellect Disabil. 2022;35(4):1047–1059. https://doi.org/10.1111/jir.13144
(23) Esteba-Castillo S; Garcia-Alba J; Rodríguez-Hidalgo E; Vaquero L; Novell R; Moldenhauer F et al. Proposed diagnostic criteria for mild cognitive impairment in Down syndrome population. J Appl Res Intellect Disabil. 2022;35(2):495–505. https://doi.org/10.1111/jar.12959
(24) Startin CM; Rodger E; Fodor-Wynne L; Hamburg S; Strydom A. Developing an informant questionnaire for cognitive abilities in Down syndrome: The Cognitive Scale for Down Syndrome (CS-DS). PLoS One. 2016;11(5):e0154596. https://doi.org/10.1371/journal.pone.0154596
(25) Del Hoyo Soriano L; Sandkühler K; Videla L; Benejam B; Carmona-Iragui M; Wlasich E et al. Discrepancies in assessing intellectual disability
levels in adults with Down syndrome: Implications for dementia diagnosis. Alzheimer's Dement. 2025;21(6):e70307. https://doi.org/10.1002/alz.70307
(26) An X; He J; Bi B; Wu G; Xu J; Yu W; Ren Z. The application of artificial intelligence in diagnosis of Alzheimer's disease: A bibliometric analysis. Front Neurol. 2024;15:1510729. https://doi.org/10.3389/fneur.2024.1510729
(27) Bostelmann M; Ruggeri P; Rita Circelli A; Costanzo F; Menghini D; Vicari S et al. Path integration and cognitive mapping capacities in Down and Williams syndromes. Front Psychol. 2020;11:571394. https://doi.org/10.3389/fpsyg.2020.571394
(28) Shimizu E; Goto-Hirano K; Motoi Y; Arai M; Hattori N. Symptoms and age of prodromal Alzheimer’s disease in Down syndrome: A systematic review and meta-analysis. Neurol Sci. 2024;45:2445–2460. https://doi.org/10.1007/s10072-023-07292-9
(29) Benejam B; Videla L; Vilaplana E; Barroeta I; Carmona-Iragui M; Altuna M et al. Diagnosis of prodromal and Alzheimer’s disease dementia in adults with Down syndrome using neuropsychological tests. Alzheimers Dement (Amst). 2020;12(1):e12047. https://doi.org/10.1002/dad2.12047
(30) Oliver C; Adams D; Holland AJ; Brown SSG ; Ball S; Dodd K et al. Acquired mild cognitive impairment in adults with Down syndrome: Age-related prevalence derived from single point assessment data normed by degree of intellectual disability. Int J Geriatr Psychiatry. 2022;37(2). https://doi.org/10.1002/gps.5674
(31) Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet. 2020;395(10242):1988–1997. https://doi.org/10.1016/S0140-6736(20)30689-9
(32) Rafii MS; Wishnek H; Brewer JB; Donohue MC; Ness S; Mobley WC et al. The Down Syndrome Biomarker Initiative (DSBI) pilot: Proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in Down syndrome. Front. Behav. Neurosci. 2015;9:239. https://doi.org/10.3389/fnbeh.2015.00239
(33) Alcolea D; Beeri MS; Rojas JC; Gardner RC; Lleó A. Blood biomarkers in neurodegenerative diseases: Implications for the clinical neurologist.
Neurology. 2023;101(4):172-180. https://doi.org/10.1212/wnl.0000000000207193
(34) Handen BL; Mapstone M; Hartley S; Andrews H; Christian B; Lee JH et al. The Alzheimer’s Biomarker Consortium–Down Syndrome (ABC-DS): A 10-year report. Alzheimers Dement. 2025;21(5):e70294. https://doi.org/10.1002/alz.70294
(35) Head E. Adapting cognitive tools for clinical trials in Down syndrome. NeurologyLive. 2025. https://www.neurologylive.com/view/adaptingcognitive-tools-clinical-trials-down-syndrome-elizabeth-head
(36) Jun P; Chengye H; Hui W. Bibliometric analysis of rehabilitation in Alzheimer's disease (2000–2023): trends, hotspots and prospects. Front Aging Neurosci. 2024;16:1457982. https://doi.org/10.3389/fnagi.2024.1457982
(37) Nadeau PA; Jobin B; Boller B. Diagnostic sensitivity and specificity of cognitive tests for mild cognitive impairment and Alzheimer’s disease in
patients with Down syndrome: A systematic review and meta-analysis. J Alzheimers Dis. 2023;95(1):13-51. https://doi.org/10.3233/JAD-220991
(38) IN FOCO P. Consejo General de la Psicología de España. Demencia y personas con discapacidades intelectuales: guía para la evaluación,
diagnóstico, intervenciones y apoyo. Infocop. 2025. https://www.infocop.es/la-atencion-a-la-demencia-en-personas-condiscapacidades-intelectuales-guia-de-la-bps/
(39) National Task Group on Intellectual Disabilities and Dementia Practices (NTG ). NTG-Early Detection Screen for Dementia (NTG -EDSD).
How to Cite
VANCOUVER
ACM
ACS
APA
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Download Citation
License
Copyright (c) 2025 María Zacarés Herrero, Jorge San José Tárrega, Silvia Trujillo Barberá, María Ángeles Rodríguez Herrera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published by Avances en Enfermería are licensed under the Creative Commons Attribution 4.0 International License. Starting 2020, we added the CC-BY-NC recognition to the license, which means anyone is allowed to copy, redistribute, remix, transmit and transform our contents with non-commercial purposes, and although new works must adequately cite the original work and source and also pursue non-commercial purposes, users do not have to license derivative works under the same terms.
